Abstract
Ever since the correlation was found between the pathogenesis of diseases and genomic alterations, molecular cytogenetic techniques have found a place in molecular medicine. These techniques are used in tracing gene and genomic abnormalities that are underlying in the development of cancer and genetic diseases. In 1969, Gall and Pardue introduced a technique known as “in situ hybridization” (ISH) to localize nucleic acids in individual cells (1). At that time, the capabilities of ISH were limited to highly repetitive sequences using radioactively labeled probes that were subsequences visualized by autoradiography. The use of radioisotopes has many disadvantages and has been replaced in DNA ISH by nonradioactive detection methods. The most commonly used reporter molecules are haptens, such as biotin and digoxigenin, which can be incorporated easily in the probe DNA. The tagged probes are then detected with labeled antibodies against the specific tag or, as in the case of biotin, with a labeled avidin molecule. Since the first report of fluorescent in situ hybridization (FISH) (2), the principle of FISH has remained essentially the same, with the exception that biotin and digoxigenin have partly been replaced by directly fluorochrome-conjugated nucleotides, which simplifies the laboratory protocol.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Gall, J. G. and Pardue, M. L. (1969) Formation and detection of RNA-DNA hybrid molecules in cytological specimens. PNAS 63, 378–383.
Pinkel, D., Straume, T., and Gray, J. (1986) Cytogenetic analysis using quantitative high sensitivity fluorecense hybridization. PNAS 83, 2934–2938.
Hopman, A. H., Claessen, S., and Speel, E. J. (1997) Multi-colour brightfield in situ hybridisation on tissue sections. Histochem. Cell. Biol. 108, 291–298.
Tanner, M., Gancberg, D., Di Leo, A., et al. (2000) Chromogenic in situ hybridization (CISH): a practical new alternative for FISH in detection of HER-2/neu oncogene amplification. Am. J. Pathol. 157, 1467–1472.
Davison, J. M., Morgan, T. W., Hsi, B. L., et al. (1998) Subtracted, unique-sequence, in situ hybridization: experimental and diagnostic applications. Am. J. Pathol. 153, 1401–1409.
Tanner, M., Järvinen, P., and Isola, J. (2001) Amplification of HER-2/neu and topoisomerase IIoc in primary and metastatic breast cancer. Cancer Res. 61, 5345–5348.
Pauletti, G., Godolphin, W., Press, M. F., et al. (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13, 63–72.
Press, M. F., Bernstein, L., Thomas, P. A., et al. (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15, 2894–2904.
Ross, J. S. and Fletcher, J. A. (1999) HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am. J. Clin. Pathol. 112, S53–S67.
Dandachi, N., Dietze, O., and Hauser-Kronberger, C. (2002) Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab. Invest. 82(8), 1007–1014.
Isola, J., Tanner, M., Salminen, T., et al. HER-2/neu oncogene status by chromogenic in situ hybridization and immunohistochemistry: a study on 1,728 breast cancer patients. (Submitted.)
Kumamoto, H., Sasano, H., Taniguchi, T., et al. (2001) Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. Pathol. Int. 51(8), 579–584
Rummukainen, J., Salminen, T., Lundin, J., et al. (2001) Comparison of c-myc oncogene amplification by chromogenic in situ hybridization (CISH) and FISH in archival breast cancer tissue array samples. Lab. Invest. 81, 1545–1552.
Savinainen, K., Linja, M., Saramäki, O., et al. (2002) Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am. J. Pathol. 160, 339–345.
Tanskanen, M., Jahkola, T., Asko-Seljavaara, S., et al. (2003) HER-2 oncogene amplification in extramammary Paget’s disease. Histopathology, in press.
Tubbs, R., Pettay, J., Skacel, M., et al. (2002) Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification. Am. J. Pathol. 160(5), 1589–1595.
Zhao, J., Wu, R., Au, A., et al. (2002) Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod. Pathol. 15(6), 657–665.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Isola, J., Tanner, M. (2004). Chromogenic In Situ Hybridization in Tumor Pathology. In: Roulston, J.E., Bartlett, J.M.S. (eds) Molecular Diagnosis of Cancer. Methods in Molecular Medicine, vol 97. Humana Press. https://doi.org/10.1385/1-59259-760-2:133
Download citation
DOI: https://doi.org/10.1385/1-59259-760-2:133
Publisher Name: Humana Press
Print ISBN: 978-1-58829-160-8
Online ISBN: 978-1-59259-760-4
eBook Packages: Springer Protocols